NCT Number: NCT07045844
The goal of this clinical trial is to evaluate whether supplementing with pasteurized donor human milk (pHDM) or preterm formula (PTF) when own mother's milk (OMM) is insufficient can improve outcomes in very preterm infants born before 29 weeks of gestation. It also aims to assess whether routine use of human milk fortifiers benefits this population. The main questions it aims to answer are:
Does supplementing OMM with pHDM or PTF improve survival without surgery-requiring necrotizing enterocolitis (NEC) by 34 weeks corrected gestational age? Is routine fortification of human milk better than selective fortification based on growth faltering?
Researchers will compare:
pHDM vs. PTF to see which better supports survival without severe NEC. Routine fortification vs. selective fortification to assess the impact on growth and long-term neurodevelopment.
Participants will:
Be randomized twice:
* First, within the first week of life to receive either pHDM or PTF when OMM is insufficient * Second, in the second week of life to receive either routine fortification or selective fortification only if growth faltering occurs Receive feeding and care as per standard clinical practice Complete neurodevelopmental assessment at 2 years corrected age using the PARCA-R tool (no additional study visits required) This multicenter, double-randomized, open-label randomized controlled trial is embedded in routine neonatal care and uses real-world data to assess both short- and long-term outcomes.
COLLABORATE-China is being run in partnership with the UK-wide COLLABORATE trial sponsored by Imperial College London.
Trial opening soon.
Get Notified1 day–14 day
All sexes
Interventional
Not applicable
The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants receive pasteurized donor human milk (pHDM) as supplemental feeding when the clinician determines maternal milk supply is insufficient.
Randomization 1 will occur when the clinician determines that supplemental feeding is required due to insufficient breast milk supply.
Participants receive preterm formula (PTF) as supplemental feeding when the clinician determines maternal milk supply is insufficient.
Randomization 1 will occur when the clinician determines that supplemental feeding is required due to insufficient breast milk supply.
Randomization 2 will be conducted when the total daily intake of human milk (including own mother's milk [OMM] and/or donor pasteurized human milk [pHDM] ) reaches between 60-120 mL/kg
Randomization 2 will be conducted: Add fortifiers when the infant meets predefined criteria for growth faltering (Preterm infants exhibit a sustained decline in growth velocity for weight, length, or head circumference, demonstrated by a downward crossing of centiles on growth curves, despite tolerating and consuming at least 180 mL/kg/day of breast milk or formula. Blood urea levels in these infants remain consistently below 1.5 mmol/L, and there are no severe complications such as active sepsis or the need for vasoactive medications to maintain circulatory stability. Chronic sodium depletion has also been ruled out, as this condition alone can lead to growth failure. Additionally, preterm infants are unable to tolerate high-volume feeding of 180 mL/kg/day due to specific reasons, such as severe gastroesophageal reflux or the presence of a high-output stoma following surgical procedures).
Time frame: 34 weeks corrected gestational age
Survival to 34 weeks corrected gestational age without surgical necrotizing enterocolitis (NEC)
Time frame: 34 weeks gestational age
Time frame: 28 days after birth
Time frame: From birth until hospital discharge (up to approximately 44 weeks postmenstrual age)
Survival: Survival outcome indicators measure the success of enduring life-threatening conditions, eg. survival rate.
Time frame: From birth until hospital discharge (up to approximately 44 weeks postmenstrual age)
Medically treated NEC: Diagnosis of necrotizing enterocolitis that required medical (non-surgical) treatment, such as bowel rest and antibiotic therapy.
Time frame: From birth until hospital discharge (up to approximately 44 weeks postmenstrual age)
Treated retinopathy of prematurity (ROP): ROP that progressed to a stage requiring medical or surgical intervention, including laser therapy or intravitreal injections.
Time frame: From birth until hospital discharge (up to approximately 44 weeks postmenstrual age)
Hearing impairment: Documented hearing loss identified through newborn hearing screening or diagnostic audiology tests, potentially requiring follow-up or intervention.
Time frame: From birth until hospital discharge (up to approximately 44 weeks postmenstrual age)
Severe brain injury: Presence of significant brain injury such as Grade III or IV intraventricular hemorrhage (IVH) or periventricular leukomalacia (PVL) as diagnosed by cranial imaging.
Time frame: From birth until hospital discharge (up to approximately 44 weeks postmenstrual age)
Length of hospital stay: Total number of days from birth until discharge from the hospital.
Time frame: From birth until hospital discharge (up to approximately 44 weeks postmenstrual age)
Number of episodes of bloodstream infection: Total number of confirmed bloodstream infections (positive blood cultures) during the hospital stay.
Time frame: From birth until hospital discharge (up to approximately 44 weeks postmenstrual age)
Number of days of antibiotic treatment: Cumulative number of days the infant received systemic antibiotic therapy during hospitalization.
Time frame: From birth until hospital discharge (up to approximately 44 weeks postmenstrual age)
Number of days on parenteral nutrition: Total number of days the infant received intravenous nutritional support due to inability to tolerate full enteral feeds.
Time frame: From birth until hospital discharge (up to approximately 44 weeks postmenstrual age)
Number of days of NPO: Total number of days the infant was designated "nil per os" (NPO), meaning no enteral feeding was given.
Time frame: From birth until 2 years corrected age.
Growth parameters (weight): Measurements of the infant's body weight at 2 years corrected age.
Time frame: From birth until 2 years corrected age.
Body length: Measurements of the infant's body length at 2 years corrected age.
Time frame: From birth until 2 years corrected age.
Head circumference: Measurements of the infant's head circumference at 2 years corrected age.
Time frame: At 2 years corrected age
Survival without moderate to severe cognitive or language impairment. PARCA-R stands for Parent Report of Children's Abilities-Revised. It is a parent completed questionnaire that can be used to assess children's cognitive and language development at 24 months of age.
Contact information is provided by the study sponsor or research team.
The Children's Hospital of Zhejiang University School of Medicine
Other
The Effects of Different Enteral Feeding Regimens on Necrotizing Enterocolitis, Mortality, and Neurodevelopment in Very Preterm Infants: A Multicenter Double-Randomized Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06765863
Very Low Birthweight, Very Preterm Infant
Ballary, Karnataka, India
View Trial DetailsNCT06810154
Digestive System Diseases, Enterocolitis
Calgary, Alberta, Canada
View Trial DetailsNCT06727877
Digestive System Diseases, Enterocolitis
Clermont-Ferrand, France
View Trial DetailsNCT00747851
Digestive System Diseases, Enterocolitis
Salt Lake City, Utah, United States
View Trial Details